Description of Procept Biorobotics's Business Segments

Procept Biorobotics Corporation specializes in the development and commercialization of advanced surgical robotic systems, primarily targeting the urology sector. The company is dedicated to enhancing surgical precision and patient outcomes through innovative robotic technology. Below is an extensive overview of the various segments, products, and services associated with Procept Biorobotics Corporation:

Segments

1. Robotic Surgery:
- Procept focuses on robotic-assisted surgical procedures, particularly within urology. Their systems aim to streamline surgical workflows, increase accuracy, and reduce recovery times for patients.

2. Urology:
- This is the core focus area for Procept. The company develops technology specifically for treating urologic conditions, including benign prostatic hyperplasia (BPH) and prostate cancer. Their robotic systems help physicians perform minimally invasive surgeries more effectively.

3. Research and Development:
- Procept invests heavily in R&D to advance their robotic technologies and expand their applications. This segment is crucial for continuous innovation and meeting the evolving needs of surgeons and patients.

4. Clinical Training and Support:
- The company provides training and ongoing support for medical professionals utilizing their robotic systems, ensuring that surgeons are well-versed in the technology and can maximize its potential in the surgical setting.

Products

1. PROCEPT Biorobotics System:
- This is the flagship product, a robotic-assisted surgical system specifically designed for urologic procedures. The system allows for more precise manipulations, enhanced visualization, and improved ergonomics for surgeons.

2. Aquablation® Therapy:
- A standout procedure offered by Procept, Aquablation utilizes waterjet technology to ablate (remove) prostate tissue. The procedure is guided by real-time imaging, allowing surgeons to minimize damage to surrounding tissues, resulting in fewer side effects compared to traditional treatments.

3. Integration with Imaging Technologies:
- The robotic systems integrate with advanced imaging modalities to enhance visualization and accuracy during procedures. This integration ensures that surgeons can make informed decisions based on real-time data.

4. Accessories and Instruments:
- Procept offers a range of surgical instruments and accessories that complement their robotic systems. These tools are designed for enhanced functionality and are integral to the Aquablation procedure.

Services

1. Training Programs:
- Procept provides comprehensive training programs for medical professionals, including hands-on workshops, simulation training, and mentorship opportunities to ensure effective use of their robotic systems.

2. Clinical Support:
- The company offers clinical support services to healthcare providers, including on-site support during surgeries, troubleshooting, and assistance with system operation to enhance surgical outcomes.

3. Research Collaboration:
- Procept engages in partnerships with academic institutions and research organizations to advance the study of robotic surgical techniques and outcomes.

4. Patient Education:
- The company also focuses on educating patients about their surgical options, particularly regarding the benefits of minimally invasive techniques like Aquablation. This inclusion empowers patients in their treatment decisions.

5. Regulatory Affairs and Compliance:
- Procept navigates the regulatory landscape to ensure that their products meet necessary safety and efficacy standards. This segment plays a vital role in the development cycle of new technologies.

In summary, Procept Biorobotics Corporation is at the forefront of integrating advanced robotic technologies into urologic surgical practices, providing a comprehensive suite of products and services that enhance surgical precision, improve patient outcomes, and streamline workflows for medical professionals. Their commitment to innovation and clinical excellence positions them as a key player in the field of robotic surgery.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Procept Biorobotics Corporation Revenues by Segments


U S	86.82 %	of total Revenue
Outside of U S	13.4 %	of total Revenue
System sales and rentals U S	28.19 %	of total Revenue
System sales and rentals Outside of U S	4.65 %	of total Revenue
Handpieces and other consumables U S	51.86 %	of total Revenue
Handpieces and other consumables Outside of U S	7.68 %	of total Revenue
Service U S	6.77 %	of total Revenue
Service Outside of U S	1.07 %	of total Revenue
United States	0 %	of total Revenue
Outside the United States	0 %	of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
U S	72.02	86.82 %
Outside of U S	11.11	13.4 %
System sales and rentals U S	23.39	28.19 %
System sales and rentals Outside of U S	3.85	4.65 %
Handpieces and other consumables U S	43.02	51.86 %
Handpieces and other consumables Outside of U S	6.37	7.68 %
Service U S	5.61	6.77 %
Service Outside of U S	0.89	1.07 %
United States	0.00	0 %
Outside the United States	0.00	0 %
Total	82.95	100 %

Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
U S	19.44 %	-
Outside of U S	25.33 %	-
System sales and rentals U S	25.15 %	-
System sales and rentals Outside of U S	0 %	-
Handpieces and other consumables U S	13.17 %	-
Handpieces and other consumables Outside of U S	42.33 %	-
Service U S	56.12 %	-
Service Outside of U S	65.24 %	-
United States	0 %	-
Outside the United States	0 %	-
Total	19.93 %	-73 %

Q1 three months ended (Mar 31 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Total	-31.64	-

Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Total	-	-

Annual Report on Procept Biorobotics Corporation Divisions, Sales by Country


U S	88.01 %	of total Revenue
System sales and rentals U S	30.27 %	of total Revenue
Handpieces and other consumables U S	51.97 %	of total Revenue
Service U S	5.76 %	of total Revenue
Non-US	12.26 %	of total Revenue
System sales and rentals Non-US	4.27 %	of total Revenue
Handpieces and other consumables Non-US	7.09 %	of total Revenue
Service Non-US	0.9 %	of total Revenue

Twelve months ended 2025
PRCT s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
U S	270.38	88.01 %
System sales and rentals U S	93.00	30.27 %
Handpieces and other consumables U S	159.67	51.97 %
Service U S	17.71	5.76 %
Total	307.23	100 %
Non-US	37.68	12.26 %
System sales and rentals Non-US	13.13	4.27 %
Handpieces and other consumables Non-US	21.78	7.09 %
Service Non-US	2.77	0.9 %

Twelve months ended 2025
PRCT s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	-95.57	-

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
U S	34.87 %	-
Outside of U S	-	-
System sales and rentals U S	18.3 %	-
System sales and rentals Outside of U S	-	-
Handpieces and other consumables U S	44.44 %	-
Handpieces and other consumables Outside of U S	-	-
Service U S	56.5 %	-
Service Outside of U S	-	-
Total	37.09 %	-
Non-US	56.81 %	-
System sales and rentals Non-US	12.38 %	-
Handpieces and other consumables Non-US	99.53 %	-
Service Non-US	93.9 %	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.